128 related articles for article (PubMed ID: 22192627)
1. Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways.
Reutenauer-Patte J; Boittin FX; Patthey-Vuadens O; Ruegg UT; Dorchies OM
Am J Pathol; 2012 Feb; 180(2):749-62. PubMed ID: 22192627
[TBL] [Abstract][Full Text] [Related]
2. Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers.
Boittin FX; Petermann O; Hirn C; Mittaud P; Dorchies OM; Roulet E; Ruegg UT
J Cell Sci; 2006 Sep; 119(Pt 18):3733-42. PubMed ID: 16926189
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration.
Markovic D; Punn A; Lehnert H; Grammatopoulos DK
Biochim Biophys Acta; 2011 May; 1813(5):896-907. PubMed ID: 21338628
[TBL] [Abstract][Full Text] [Related]
4. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
[TBL] [Abstract][Full Text] [Related]
5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
6. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers.
Vandebrouck C; Martin D; Colson-Van Schoor M; Debaix H; Gailly P
J Cell Biol; 2002 Sep; 158(6):1089-96. PubMed ID: 12235126
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes.
Smani T; Calderón-Sanchez E; Gómez-Hurtado N; Fernández-Velasco M; Cachofeiro V; Lahera V; Ordoñez A; Delgado C
Cardiovasc Res; 2010 Aug; 87(3):459-66. PubMed ID: 20189952
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.
Ruegg UT; Nicolas-Métral V; Challet C; Bernard-Hélary K; Dorchies OM; Wagner S; Buetler TM
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S155-61. PubMed ID: 12206810
[TBL] [Abstract][Full Text] [Related]
9. Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle.
De Luca A; Nico B; Rolland JF; Cozzoli A; Burdi R; Mangieri D; Giannuzzi V; Liantonio A; Cippone V; De Bellis M; Nicchia GP; Camerino GM; Frigeri A; Svelto M; Camerino DC
Neurobiol Dis; 2008 Nov; 32(2):243-53. PubMed ID: 18694830
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
Reutenauer J; Dorchies OM; Patthey-Vuadens O; Vuagniaux G; Ruegg UT
Br J Pharmacol; 2008 Oct; 155(4):574-84. PubMed ID: 18641676
[TBL] [Abstract][Full Text] [Related]
11. Convergent regulation of skeletal muscle Ca2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase.
Johnson BD; Scheuer T; Catterall WA
Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4191-6. PubMed ID: 15753322
[TBL] [Abstract][Full Text] [Related]
12. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy.
Dorchies OM; Reutenauer-Patte J; Dahmane E; Ismail HM; Petermann O; Patthey- Vuadens O; Comyn SA; Gayi E; Piacenza T; Handa RJ; Décosterd LA; Ruegg UT
Am J Pathol; 2013 Feb; 182(2):485-504. PubMed ID: 23332367
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice.
Schertzer JD; Ryall JG; Lynch GS
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899
[TBL] [Abstract][Full Text] [Related]
14. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
Harcourt LJ; Schertzer JD; Ryall JG; Lynch GS
Neuromuscul Disord; 2007 Jan; 17(1):47-55. PubMed ID: 17134898
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of L-arginine benefits mdx skeletal muscle function.
Barton ER; Morris L; Kawana M; Bish LT; Toursel T
Muscle Nerve; 2005 Dec; 32(6):751-60. PubMed ID: 16116642
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
[TBL] [Abstract][Full Text] [Related]
17. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
18. Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice.
Pereira JA; Taniguti AP; Matsumura C; Marques MJ; Neto HS
Muscle Nerve; 2012 Sep; 46(3):400-6. PubMed ID: 22907231
[TBL] [Abstract][Full Text] [Related]
19. Selective activation of α7 nicotinic acetylcholine receptor (nAChRα7) inhibits muscular degeneration in mdx dystrophic mice.
Leite PE; Gandía L; de Pascual R; Nanclares C; Colmena I; Santos WC; Lagrota-Candido J; Quirico-Santos T
Brain Res; 2014 Jul; 1573():27-36. PubMed ID: 24833065
[TBL] [Abstract][Full Text] [Related]
20. Combined XIL-6R and urocortin-2 treatment restores MDX diaphragm muscle force.
Manning J; Buckley MM; O'Halloran KD; O'Malley D
Muscle Nerve; 2017 Dec; 56(6):E134-E140. PubMed ID: 28294390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
